austin health succimer powder for injection
austin health - injection, powder for - excipient ingredients: succimer; stannous chloride; ascorbic acid; inositol; hydrochloric acid; sodium hydroxide - diagnostic agent when radiolabelled for renal cortical scintigraphy
chemet 100mg capsules
imported (united states) - succimer - oral capsule - 100mg
renocis 1mg kit for radiopharmaceutical preparation
curium pharma uk ltd - succimer - kit for radiopharmaceutical preparation - 1mg
sumer 100mg capsule
succimer - capsule - 100mg - antidotes
rotop - dmsa- kit for the preparation of technetium tc99m succimer injection injection, powder, lyophilized, for solution
rotop pharmaka gmbh - 2,3-dimercaptosuccinic acid (unii: 4s9ju7xf01) (2,3-dimercaptosuccinic acid - unii:4s9ju7xf01) - 2,3-dimercaptosuccinic acid 1 mg - rotop - dmsa is a radiodiagnostic pharmaceutical. the kit contains the non-radioactive powder for reconstitution of the [99m tc]technetium succimer injection solution ([99m tc]-dmsa). the sodium [99m t]pertechnetat which is needed for the preparation is not part of this kit. after labelling with sodium [99m tc]technetium pertechnetat solution, rotop - dmsa is used for static renal scintigraphy when adequate diagnostics are not possible using other diagnostic procedures (such as ultrasound): - to identify focal renal parenchymal changes (e.g. in the case of renal infarction) - to identify norm variants such as atypical double kidney, small kidney, dysplastic kidney, horseshoe kidney, as well as to identify ectopic kidneys - to confirm absence of renal function in multicystic kidneys. take special care with rotop – dmsa rotop - dmsa is not suitable for determining global renal function from the dmsa accumulation. in the case of proximal tubulopathies [99m tc]dmsa does not lead to a sufficient diagnostic renal a
technescan dmsa 1.2 mg kit for radiopharm. prep. i.v. vial
curium belgium s.p.r.l.-b.v.b.a. - succimer 1,2 mg - kit for radiopharmaceutical preparation - 1,2 mg - dimercaptosuccinic acid 1.2 mg - technetium (99mtc) succimer
renocis 1 mg kit for radiopharmaceutical preparation
cis bio international - dimercaptosuccinic acid - kit for radiopharmaceutical preparation - 1 mg - technetium (99mtc) compounds; technetium (99mtc) succimer
dmsa radpharm
ansto t/a ansto health - stannous chloride; succimer -
trisenox
medison pharma ltd - arsenic trioxide - solution for injection - arsenic trioxide 1 mg/ml - arsenic trioxide - arsenic trioxide - trisenox is indicated for induction of remission, and consolidation in adult patients with:• newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 1000/μl) in combination with all-trans-retinoic acid (atra)• relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.
amerscan dmsa agent
ge healthcare limited - succimer - unknown